Every year, thousands of patients require complex cranial reconstruction following trauma, tumor removal, congenital conditions, or other neurological procedures. For surgeons, success depends on more than surgical expertise; it depends on having access to implants that fit precisely, arrive quickly, and support long-term healing.
That challenge has become Kelyniam’s specialty.
Founded in 2011, Kelyniam has established itself as a leader in regenerative neurosurgery through the development and manufacture of patient-specific cranial and craniofacial implants. Operating from its Connecticut headquarters, the company has built a reputation for combining advanced engineering, regenerative biomaterials, and rapid production capabilities to support some of the most demanding procedures in modern medicine.
Kelyniam’s core mission centers on improving outcomes for patients who require cranial reconstruction. Rather than relying on standard, one-size-fits-all solutions, the company designs implants tailored to each individual patient’s anatomy, enabling surgeons to achieve a highly accurate fit while streamlining surgical procedures. The approach has helped position Kelyniam at the forefront of a growing movement toward personalized medicine.
“Feedback from neurosurgeons drives our product development,” said Ross Bjella, CEO of Kelyniam Global. “Regenerative medicine is clearly the future of neurosurgery. Every patient deserves a custom solution, and implants that integrate with the patients’ natural bone can deliver superior outcomes. That’s why we’re focused on developing and licensing regenerative technologies that neurosurgeons want.”
A defining feature of Kelyniam’s business model is speed. While custom medical devices have traditionally required lengthy manufacturing timelines, Kelyniam can design, manufacture, and ship many patient-specific implants within 24 to 48 hours of surgeon approval. That rapid turnaround supports hospitals not only in urgent cases but also in planned procedures, where shorter timelines may allow for reduced length of stay and more efficient care delivery.
The company’s innovation extends far beyond manufacturing speed. Kelyniam has invested heavily in regenerative technologies that encourage biological integration and healing. Among its offerings are hydroxyapatite-based implants, biomimetic devices designed to resemble the mineral composition of natural bone. These implants have gained attention for their osteoconductive properties and their potential to support physiological bone regeneration.
Kelyniam has also introduced next-generation biphasic calcium phosphate-enhanced PEEK implants, marketed under its Fusion™ platform. The material combines the strength and durability of PEEK with calcium phosphate components commonly found in human bone. The result is an implant designed not only to restore structural integrity but also to encourage enhanced osseointegration. In 2025, Kelyniam received FDA clearance for the Fusion™ implant, marking a significant milestone in cranial implant technology.
“Our vision is to lead the future of regenerative neurosurgery,” Mr. Bjella says. “We continually look for ways to combine advanced biomaterials with patient-specific design, so surgeons have access to solutions that support both reconstruction and regeneration.”
Innovation at Kelyniam is equally evident in its proprietary technology. The company remains the only cranial implant manufacturer with a patented Integrated Fixation System (IFS), a design that incorporates fixation tabs directly into the implant itself. By reducing or eliminating the need for additional cranial plating hardware, the technology can simplify procedures, potentially reduce operating time, and improve surgical efficiency.
The company’s manufacturing process reflects its commitment to precision. Using advanced imaging data, computer-aided design software, 3D printing technology, and CNC manufacturing, Kelyniam creates implants that match patient anatomy with exceptional accuracy. Surgeons are actively involved throughout the workflow, ensuring that each device meets the specific clinical requirements of the case.
Since launching its first custom PEEK cranial implants in 2011, Kelyniam has steadily expanded its regenerative portfolio while strengthening relationships with neurosurgeons and healthcare institutions across the United States and internationally. Recent growth has been fueled by increasing adoption of regenerative solutions and continued demand for customized cranial reconstruction technologies.
What distinguishes Kelyniam most is its ability to bridge advanced science with practical clinical needs. The company’s products are not developed in isolation; they are created through close collaboration with surgeons who face complex reconstructive challenges every day. That surgeon-driven philosophy has helped Kelyniam build a reputation for responsiveness, reliability, and innovation.
As regenerative medicine continues to reshape the future of healthcare, Kelyniam is positioning itself at the center of that transformation. Through patient-specific design, pioneering biomaterials, patented technologies, and industry-leading turnaround times, the company is helping redefine what is possible in cranial reconstruction.
For patients facing life-changing procedures and surgeons seeking the best possible tools, Kelyniam’s work represents more than technological advancement. It represents a future where precision medicine and regenerative science work together to restore both form and function, one patient at a time.
